Arrowhead Plozasiran Phase 3 SHASTA-3 and SHASTA-4 12-Month Data at ESC 2026 Munich Show 79-81% Triglyceride Reduction and Pooled Reduction in Acute Pancreatitis Events
Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented Sunday August 30, 2026 the full Phase 3 SHASTA-3 and SHASTA-4 12-month data of plozasiran (an RNAi therapeutic targeting APOC3, administered as quarterly subcutaneous injection) in adults with severe hypertriglyceridemia at the European Society of Cardiology Congress 2026 in Munich, Germany, in a Hot Line Late-Breaking Science session. SHASTA-3 and SHASTA-4 met their primary and all prespecified secondary endpoints with median triglyceride reductions from baseline of 79% and 81%, respectively, at Month 12 (p<0.0001 in both studies). More than 90% of plozasiran-treated patients achieved triglycerides below 500 mg/dL at Month 12, and more than half achieved TG below 150 mg/dL. In a prespecified pooled analysis, plozasiran significantly reduced acute pancreatitis events across the broad sHTG study population, with greater absolute benefit among higher-AP-risk patients. Three fatal events in the plozasiran arm (two cardiovascular deaths, one CMML death) were assessed as unrelated to study treatment. Arrowhead plans to file a supplemental NDA before end of 2026 for the broader sHTG population, building on the earlier familial chylomicronemia syndrome approval.